MDXG MiMedx Group Inc.

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall

MIMEDX to Sponsor and Attend Symposium on Advanced Wound Care (SAWC) Fall

To Present Six Posters Featuring the Company’s Latest Product Innovations

MARIETTA, Ga., Sept. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced its schedule for the Symposium on Advanced Wound Care (SAWC) Fall meeting taking place September 3-6 in Las Vegas, NV. SAWC remains a premier event for clinicians and industry professionals to explore the latest clinical evidence and innovations in advanced wound care. The Company will showcase its leading advanced wound care portfolio in the exhibit hall at booth 511.

Sponsored Lunch Symposium

Title: Change is Inevitable: Mastering the Art of Wound Healing in an Evolving Landscape

Date: Thursday, September 4, 2025

Time: 11:40 – 1:10 p.m. PDT

Faculty: Paul Kim, DPM, MS, FACFAS; Nicolas Mouawad, MD, MPH, MBA, DFSVS, FRCS, FACS, RPVI; Scott Boynton, DPM, FACFAS

Description: Wound care is constantly evolving, and clinicians must adapt to an ever-changing landscape of patient complexities and clinical challenges. In this dynamic symposium, Drs. Paul Kim, Nicolas Mouawad, and Scott Boynton will discuss advanced treatment approaches that support clinicians in optimizing wound healing across diverse patient populations and present challenging real-world cases.

Accepted Poster Presentations

The Company is pleased to announce that six clinical and scientific posters have been accepted and will be on display in the poster hall.

  • Therapeutic Potential of Amniotic Tissue in Promoting Pigment Restoration During Wound Healing
  • Bovine Extracellular Matrix Particulate Modulates Fibroblast Cellular Activities Supportive of Wound Management
  • Characterization of PURION® Processed Dual Layer Chorion Allograft
  • Amniotic Membrane Allografts promote re-epithelialization in vitro via cJUN Mediated Mechanism
  • Adjunctive Dehydrated Human Amnion Chorion Membrane Usage for Pressure Injuries in the Post-Acute Care Setting
  • Reconstruction Following Mohs Surgery with a Placental Allograft: A Cost-Effectiveness Analysis  

About MIMEDX

MIMEDX is a pioneer and leader focused on helping humans heal. With more than a decade of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX is dedicated to providing a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company’s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life. For additional information, please visit .

Contact:

Matt Notarianni

Investor Relations

470-304-7291



EN
03/09/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on MiMedx Group Inc.

 PRESS RELEASE

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule

MIMEDX Comments on CY 2026 Medicare Physician Fee Schedule Final Rule Company is Well Positioned to Continue to Compete and Grow MARIETTA, Ga., Nov. 03, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today commented on the Centers for Medicare and Medicaid Services (“CMS”) release of the CY 2026 Physician Fee Schedule (“PFS”) final rule, which was published on Friday. “Over the last several years, we have actively engaged with numerous stakeholders to advocate for much-needed reform of the Medicare reimbursement system for skin substitutes. CMS i...

 PRESS RELEASE

MIMEDX Announces Record Revenue for Third Quarter 2025

MIMEDX Announces Record Revenue for Third Quarter 2025 Second Consecutive Quarter of Highest Quarterly Net Sales in MIMEDX History  Third Quarter Net Sales of $114 million Grew 35% Year-Over-Year Third Quarter GAAP Net Income and Diluted Earnings Per Share were $17 Million and $0.11, Respectively Third Quarter Adjusted EBITDA was $35 Million, or 31% of Net Sales Raises 2025 Net Sales Growth and Adjusted EBITDA Expectations Management to Host Conference Call Today, October 29, 2025, at 4:30 PM ET MARIETTA, Ga., Oct. 29, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MI...

 PRESS RELEASE

MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conf...

MIMEDX to Host Third Quarter 2025 Operating and Financial Results Conference Call on October 29 MARIETTA, Ga., Oct. 15, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the third quarter ended September 30, 2025 after the market close on Wednesday, October 29, 2025. The MIMEDX senior management team will host a webcast and conference call to review its results beginning at 4:30 p.m. Eastern Time on the same day. The conference call can be accessed using the following informat...

 PRESS RELEASE

MIMEDX Announces Launch of EPIXPRESS®

MIMEDX Announces Launch of EPIXPRESS® Next-Generation, Lyophilized Human Placental Allograft Further Expands Company’s Broad Portfolio of Advanced Wound Care (“AWC”) Products MARIETTA, Ga., Oct. 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the launch of EPIXPRESS®, the Company’s newest addition to its portfolio of AWC solutions. “I am pleased to announce our latest, organically developed addition to our product portfolio today with the launch of EPIXPRESS,” said Joseph H. Capper, MIMEDX Chief Executive Officer. “With EPIXPRE...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch